LPCN

Lipocine Inc. LPCN

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,913 of 2,925

Why it scores 7Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$190.1K

Quarter to Jun 30

Net income

$-2.62M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$7.63M total
Squadron Capital Management LLC
$2.07M+80.0%
Ikarian Capital, LLC
$1.30M0.0%
Eversept Partners, LP
$755.2K0.0%
VANGUARD CAPITAL MANAGEMENT LLC
$590.9K+15.0%
ACADIAN ASSET MANAGEMENT LLC
$435.0KNew
BOOTHBAY FUND MANAGEMENT, LLC
$359.6K0.0%
JANE STREET GROUP, LLC
$243.8K+375.5%
BlackRock, Inc.
$228.5K0.0%
TWO SIGMA INVESTMENTS, LP
$217.3K+151.5%
CITADEL ADVISORS LLC
$207.9K+179.2%
Seven Fleet Capital Management LP
$201.8K-36.9%
GEODE CAPITAL MANAGEMENT, LLC
$190.8K+18.0%
RENAISSANCE TECHNOLOGIES LLC
$177.2K+79.8%
VANGUARD FIDUCIARY TRUST CO
$139.6K+68.3%
DIMENSIONAL FUND ADVISORS LP
$94.1K+92.3%
HRT FINANCIAL LP
$74.0KNew
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$65.0K+1.9%
STATE STREET CORP
$57.4K0.0%
GSA CAPITAL PARTNERS LLP
$48.0KNew
Birchview Capital, LP
$42.8K-85.1%
NORTHERN TRUST CORP
$40.8K+22.2%
PRICE T ROWE ASSOCIATES INC /MD/
$32.0KNew
BARCLAYS PLC
$25.2K+4.4%
UBS Group AG
$9.2K+2.9%
WELLS FARGO & COMPANY/MN
$6.9K0.0%
See all 36 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/LPCN

Earnings Per Share

13fpro.ai/company/LPCN

Loading ratio trend…

LPCN key financials by period

Reported revenue, net income and operating margin by fiscal year, from Lipocine Inc.'s annual filings on SEC EDGAR.

Lipocine Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$2.0M$-9.6M—
FY 2024$11.2M$8.4K-10.3%
FY 2023$-2.9M$-16.4M—
FY 2022$500.0K$-10.8M—
FY 2021$16.1M$-634.4K19.5%
FY 2019$165.0K$-13.0M—
Source: LPCN filings on SEC EDGAR →

LPCN insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Lipocine Inc. (LPCN): stock profile, AI score and financials

Lipocine Inc. (LPCN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LPCN at 6.5/100 on a composite quality score built from its SEC filings, placing it at rank #2,913 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Lipocine Inc. reports quarterly revenue of $190.1K, net income of $-2.6M. Top institutional holders of LPCN by reported 13-F value include Squadron Capital Management, Ikarian Capital, Eversept Partners, based on the most recent SEC filings. LPCN trades on the Nasdaq exchange and files with the SEC under CIK 1535955. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LPCN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Lipocine Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1535955 →